Avid Bioservices Inc (CDMO)

[EYEBUYSTOX]

Yes, that is him. Also an interesting coincidence (though probably nothing) is that Paul Rennert of Sugarcone Biotech Blog showed an initial interest in Bavituximab on March 2 in his very thorough piece outlining the immunotherapy landscape. We know what happened 3 days later. Today, he is again trumpeting the PS technology having viewed some of the data at AACR. In his words on twitter, "Impressive really". It's always good to keep tabs on sudden changes of heart relating to PS when they come from people who link Chimera research on their home page. Just something to follow.